Characteristic | RA > 3 Years, n = 2,947 | RA ≤ 3 Years, n = 936 | p (for % difference between established and early RA) |
---|---|---|---|
Sex, n (%) | |||
Male | 640 (22.0) | 246 (26.5) | < 0.004 |
Female | 2,273 (78) | 681 (73.5) | < 0.004 |
Age (mean ± SD) yrs | 58.2 ± 12.6 | 54.4 ± 14.6 | < 0.0001 |
Disease duration, median yrs | 12 | 2 | < 0.0001 |
Race/ethnicity, n (%) | |||
Caucasian | 2,483 (85.9) | 779 (85.1) | 0.541 |
African American | 129 (4.5) | 60 (6.6) | 0.011 |
Asian | 47 (1.6) | 14 (1.5) | 0.839 |
Hispanic | 171 (5.9) | 44 (4.8) | 0.205 |
Other | 59 (2.0) | 18 (2.0) | 0.888 |
Education, n (%) | |||
Primary/secondary | 1,270 (46.1) | 372 (42.8) | 0.085 |
College | 1,485 (53.9) | 498 (57.2) | 0.085 |
Disability index (HAQ) | 0.4 ± 0.5 | 0.4 ± 0.4 | 0.149 |
DAS28 | 3.8 ± 1.6 | 3.8 ± 1.6 | 0.696 |
TJC | 9.8 ± 10.4 | 10.8 ± 11.4 | 0.018 |
SJC | 5.3 ± 6.0 | 5.4 ± 6.4 | 0.553 |
MD VAS global (0–100mm) | 27.7 ± 22.0 | 29.6 ± 22.8 | 0.024 |
Patient VAS global (0–100 mm) | 31.9 ± 25.8 | 31.9 ± 25.5 | 0.966 |
Patient VAS pain (0–100 mm) | 34.5 ± 26.3 | 35.3 ± 26.1 | 0.443 |
ESR, mm/h | 25.7 ± 22.9 | 25.0 ± 23.0 | 0.593 |
CRP, mg/dl | 3.1 ± 10.4 | 1.9 ± 4.2 | 0.055 |
Prednisone, per day* | 3.8 ± 1.5 | 4.2 ± 1.6 | 0.0001 |
Number of prior DMARD failed | 0.9 ± 0.6 | 0.8 ± 0.6 | 0.457 |
↵* Prednisone dose is categorical variable where 1 = 1 mg, 2 = 2–2.5 mg, 3 = 3–4 mg, 4 = 5–7 mg, 5 = 7.5–9 mg, 6 = > 10 mg. HAQ: Health Assessment Questionnaire; DAS28: 28 joint disease activity score; TJC: tender joint count; SJC: swollen joint count; VAS: visual analog scale; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DMARD: disease modifying antirheumatic drugs.